Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BY.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.76NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-12311.6US
BN.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CK.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.6.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.75.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DM.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.60NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.49NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CK.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.9.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDK.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KT.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LE.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.7.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HL.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCDNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.44.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
FL.37NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.45.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FP.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.102NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GN.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.31NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.35.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GE.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HE.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.4.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.99NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HW.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.4.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FE.1.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HA.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GM.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FT.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JD.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used